BDX trades 21.4% below Wall Street's consensus target of $174.81.
Last 12 months price action with 12-month analyst target path
The base valuation assumes BDX achieves its forward estimates and maintains a stable P/E multiple of 11.4x. This scenario reflects the blended consensus of 34 Wall Street analysts, balancing both positive catalysts and macroeconomic headwinds over the next 12 months.
As of June 21, 2026, Becton, Dickinson and Company (BDX) has a Wall Street consensus price target of $174.81, based on estimates from 34 covering analysts. With the stock currently trading at $143.98, this represents a potential upside of +21.4%. The company has a market capitalization of $52.16B.
Analyst price targets range from a low of $159.00 to a high of $204.00, representing a 26% spread in expectations. The median target of $169.03 aligns closely with the consensus average.
The current analyst consensus rating is Hold, with 16 analysts rating the stock as a Buy or Strong Buy,17 rating it Hold, and 1 rating it Sell or Strong Sell. The mixed ratings reflect uncertainty about near-term direction.
From a valuation perspective, BDX trades at a trailing P/E of 24.7x and forward P/E of 11.4x. The forward PEG ratio of 0.69 suggests the stock may be undervalued relative to its growth. Analysts expect EPS to grow +210.2% over the next year.
Our proprietary valuation model, which blends historical multiples with forward estimates, suggests a base-case price target of $155.56, with bear and bull scenarios of $98.00 and $204.96 respectively. Model confidence stands at 50/100, reflecting moderate uncertainty in projections.
| Company | Market Cap | Price | Target | Upside Potential | Rating | Fwd P/E | Analysts |
|---|---|---|---|---|---|---|---|
BAXBaxter International Inc. | $10.3B | $19.89 | $20.71 | +4.1% | Hold | 10.4x | 36 |
BSXBoston Scientific Corporation | $67.3B | $45.29 | $82.90 | +83.0% | Buy | 13.5x | 44 |
MDTMedtronic plc | $101.9B | $79.34 | $95.80 | +20.7% | Buy | 13.3x | 51 |
SYKStryker Corporation | $117.9B | $307.80 | $387.46 | +25.9% | Buy | 20.5x | 51 |
ZBHZimmer Biomet Holdings, Inc. | $17.2B | $87.97 | $96.33 | +9.5% | Hold | 10.4x | 42 |
EWEdwards Lifesciences Corporation | $50.4B | $87.36 | $96.55 | +10.5% | Buy | 29.0x | 48 |
ABTAbbott Laboratories | $153.7B | $88.38 | $127.46 | +44.2% | Buy | 16.1x | 41 |
DHRDanaher Corporation | $125.4B | $177.17 | $230.89 | +30.3% | Buy | 21.0x | 43 |
TMOThermo Fisher Scientific Inc. | $172.7B | $464.61 | $599.70 | +29.1% | Buy | 18.7x | 42 |
HSICHenry Schein, Inc. | $9.2B | $79.92 | $87.43 | +9.4% | Buy | 14.9x | 33 |
Quick answers to the most common questions about buying BDX stock.
The consensus Wall Street price target for BDX is $174.81, representing 21.4% upside from the current price of $143.98. With 34 analysts covering the stock, this strong upside suggests significant value not yet reflected in today's share price.
BDX has a consensus rating of "Hold" based on 34 Wall Street analysts. The rating breakdown is mixed, with 17 Hold ratings making up the largest segment. The consensus 12-month price target of $174.81 implies 21.4% upside from current levels.
With a forward P/E of 11.4461x, BDX trades at a relatively low valuation. The consensus target of $174.81 implies 21.4% appreciation, suggesting meaningful undervaluation.
The most bullish Wall Street analyst has a price target of $204 for BDX, while the most conservative target is $159. The consensus of $174.81 represents the median expectation. Our quantitative valuation model projects a bull case target of $205 based on optimistic growth and margin assumptions. These targets typically reflect 12-month expectations.
BDX is heavily covered by Wall Street, with 34 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 16 have Buy ratings, 17 recommend Hold, and 1 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.
The 12-month BDX stock forecast based on 34 Wall Street analysts shows a consensus price target of $174.81, with estimates ranging from $159 (bear case) to $204 (bull case). The median consensus rating is "Hold". Our proprietary valuation model produces a base case fair value of $156, with bear/bull scenarios of $98/$205.
Our quantitative valuation model calculates BDX's fair value at $156 (base case), with a bear case of $98 and bull case of $205. The model uses discounted cash flow analysis, historical growth rates, and margin mean-reversion to project FY+2 earnings, then applies an appropriate P/E multiple. The model confidence score is 50/100.
BDX trades at a forward P/E ratio of 11.4x based on next-twelve-months earnings estimates compared to a trailing P/E of 24.7x. The lower forward P/E indicates analysts expect earnings growth. A forward P/E is useful for comparing valuations when earnings are expected to change significantly.
Wall Street analysts are very optimistic on BDX, with a "Hold" consensus rating and $174.81 price target (21.4% upside). 16 of 34 analysts rate it Buy or Strong Buy. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.
BDX analyst price targets range from $159 to $204, a 26% moderate spread showing some variance in outlooks. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $174.81 consensus represents the middle ground. Our model's $98-$205 range provides an independent fundamental perspective.
Deep dive into BDX consensus models and risk factors.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.